{"name":"Apotex Inc.","slug":"apotex-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1964-01-01","label":"Alkeran first approved","drug":"Alkeran","drugSlug":"melphalan","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Alkeran","genericName":"melphalan","slug":"melphalan","indication":"Malignant tumor of ovary","status":"marketed"},{"name":"Imiquimod 5%: manufactured by Apotex","genericName":"Imiquimod 5%: manufactured by Apotex","slug":"imiquimod-5-manufactured-by-apotex","indication":"Actinic keratosis","status":"phase_3"},{"name":"Imiquimod Vehicle","genericName":"Imiquimod Vehicle","slug":"imiquimod-vehicle","indication":"Actinic keratosis","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Adara 5% Cream Canada","genericName":"Adara 5% Cream Canada","slug":"adara-5-cream-canada","indication":"Inflammatory skin conditions (e.g., atopic dermatitis, contact dermatitis, eczema)","status":"phase_3"},{"name":"Adara 5% Cream US","genericName":"Adara 5% Cream US","slug":"adara-5-cream-us","indication":"Acne vulgaris (topical treatment)","status":"phase_3"}]}],"pipeline":[{"name":"Alkeran","genericName":"melphalan","slug":"melphalan","phase":"marketed","mechanism":"","indications":["Malignant tumor of ovary","Multiple myeloma"],"catalyst":""},{"name":"Adara 5% Cream Canada","genericName":"Adara 5% Cream Canada","slug":"adara-5-cream-canada","phase":"phase_3","mechanism":"Adara 5% Cream is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin.","indications":["Inflammatory skin conditions (e.g., atopic dermatitis, contact dermatitis, eczema)"],"catalyst":""},{"name":"Adara 5% Cream US","genericName":"Adara 5% Cream US","slug":"adara-5-cream-us","phase":"phase_3","mechanism":"Adara 5% Cream is a topical formulation containing adapalene, a third-generation retinoid that normalizes keratinization and reduces inflammation in the skin.","indications":["Acne vulgaris (topical treatment)"],"catalyst":""},{"name":"Imiquimod 5%: manufactured by Apotex","genericName":"Imiquimod 5%: manufactured by Apotex","slug":"imiquimod-5-manufactured-by-apotex","phase":"phase_3","mechanism":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions and certain cancers.","indications":["Actinic keratosis","Basal cell carcinoma (superficial and nodular)","Genital warts (external)","Cutaneous T-cell lymphoma (mycosis fungoides)"],"catalyst":""},{"name":"Imiquimod Vehicle","genericName":"Imiquimod Vehicle","slug":"imiquimod-vehicle","phase":"phase_3","mechanism":"Imiquimod vehicle is a topical formulation base designed to deliver imiquimod, a toll-like receptor 7/8 agonist that activates innate immune responses.","indications":["Actinic keratosis","Basal cell carcinoma","Genital warts"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNN3l1S0UzZFl4TWtvNUJwbEZvb1RJOHNIQWVyQUpWdkhXRTRuNGhlUHA1Q0lHV0ZmS0xiSHY4TDlPU1RsakdVQVRHclVWYnFWeU5FZk8yQzJWcVJ0dDU1cElrbFdpX2h0Y0FMR2lMVm96VXgwSHV6YTlQcDdJNk03VFNUSU1mTXZmTHBMenJ6cGlmLXIxYld3VXJCZFlPRGlxaGM0cFQzQ0swX2w3d19FTVRTa0kySUE?oc=5","date":"2026-03-30","type":"pipeline","source":"Castanet","summary":"Apotex announces Jeff Watson as new CEO after Allan Oberman steps down - Castanet","headline":"Apotex announces Jeff Watson as new CEO after Allan Oberman steps down","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNN3hxR1ZhbTMtZFVRZTZScGtWY1Z6bVNkLUtFWnJZQ1NYd044UXE5S0FHdUZwR3l2VDFyR2lTVUZZc002bVRzb2N3VWJFTVZEZlM1OElsWFg4V2F5R2pLckpoZTZtMVNFMHAwSnMwMktscG1ZMHNTblU2SWg5Q1F2N1pVbUtMb0ZzalNrYVIxcXFyM0NGMkMwc3YteDBDWllOOVg1RVNsQjFnS3NZMkcxOElodWd5dkhIZTVjanVR?oc=5","date":"2026-02-25","type":"patent","source":"benefitsandpensionsmonitor.com","summary":"Generic drug giant targets up to $1 billion TSX float - benefitsandpensionsmonitor.com","headline":"Generic drug giant targets up to $1 billion TSX float","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPdmxIaS1ZaHZ6al9nSHVJMHlIcHk4OFd4REU4dzlCQWFVWEkySEJfZmxMaU9DWk51MmRzTFVGTllsdWt2b0RZM0g2ajdxS19HMGRVVGI3VmhOTDV1VlVFdk02X1lCNVVKbXFRVjF6S3NGU3F0d1ZpVjhxM0JhMGFNQUR5Y25SVVpFTnhWTDJSZ1Uyb3dWRVF0VG1hdjQ?oc=5","date":"2026-02-24","type":"pipeline","source":"The Globe and Mail","summary":"Apotex plans $1-billion initial public offering - The Globe and Mail","headline":"Apotex plans $1-billion initial public offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOZDlzX2dlSWVvY2tSU21QQTY2bXJxaXkxbEktMVVEQ1pzTVVxNlhPRXYxNUVoSkJ6d05LZjl3dlVKelZUb09FSDNMN09RZlVEaVdsRTlIcHNMVmQ5Y2dTcXh0Z0JvVXB1c0dYaHhDZzVYM3ZvTHBhNm1KTnRhZmtqVVpuWW1IbnROVWNsNjctSFJFLS1zUFgtUnlyZHZwT3c2Wkw2cXJISGFPUnB6TzZjX2QyRQ?oc=5","date":"2026-02-23","type":"pipeline","source":"Bloomberg.com","summary":"Canadian Drugmaker Apotex Seeks Up to $730 Million in First-Half IPO - Bloomberg.com","headline":"Canadian Drugmaker Apotex Seeks Up to $730 Million in First-Half IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQcGl2dXotMGwzVlhSZXdrY1ZheEZ5NzdRT0tFRnUxVjZGeEZEOUJManE4V01fcWVDbEozbHBOZnZRRmtOb0dLT2s2YU85NS1HWEkzWVp1UDNyTFdnZDctdVNvUThnbzJ3cWk5ZnNqV0FOWU1JSVNNNlFjSFduZUxUN2tn0gGHAUFVX3lxTFBzaW5Mbl9JWmU0aXkyLVg0QU9CQXJsajVEakRRUFRoN2tVd3liR0habHNVazhWT2RRS2dCc21YVVVMWUlMVjFjY3g3aEhmbldpZWVmanBVR0p3S3ZFZTVzMVF4d3ZZd0FvcFBaYnZ5VW4xZEV0YTBDOXBSV3VBSHBKS1FoVlczZw?oc=5","date":"2026-02-12","type":"regulatory","source":"BioTecNika","summary":"Regulatory Affairs Job at Apotex Inc. | Analyst Role Life Science Graduates - BioTecNika","headline":"Regulatory Affairs Job at Apotex Inc. | Analyst Role Life Science Graduates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxObWp0cGNpOWRzcl9FQnZtWGY3VWhJUGtscllWWlppYTVVSlBuZ1Z5cVVEQlZscW5qV2RaMDhWVVVwaU90UXBaQVJabWxPVzl3U01oY3RkZHBzbnlXcVRtMVhlSTZldXRsTEVfN3gxcG5DTmlMRWcyZ2M1RXpRUHVTYjg4V2JrbU5jZWNFTURwQnJNZ0tNTWs5YUF3YXRQWkU5bl84bndqVlZKS2QtRlE5NGVoMHVvZ3V2MXI5UXJRNnZOcGtuTng2WWc5WFBHSmZUYnU3Q0lxeUdEYlVxaTJIQWhaT0o1YVJoTWtoTA?oc=5","date":"2026-02-05","type":"deal","source":"prnewswire.com","summary":"Apotex licenses exclusive Canadian rights to testosterone replacement therapy Nebido® from Grünenthal - prnewswire.com","headline":"Apotex licenses exclusive Canadian rights to testosterone replacement therapy Nebido® from Grünenthal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNTkdyTnI4REROaGRoYkdFQ3BXZDlqcDNUeE9VT1lHMVAtaXpua3Fnb2o2Ull3MWJUVkFhbkV4aU5jQkFxcDFGMzBBU2ZwcTRLWlQ2NDU4MWRxc1RxUkNrX3h1MnlNOGM2U0stWUxzTTZVbTBVdFE5bjdZdmtnWWg1TGdVcUd1WUJ4TEJfd0w4d2t0ajZEcXgzT2NPenZKU3JVakR2dXJKV1gwcmVwZVJPMnJmbzZxZVRDZTd3VmxrYnh1bmUteDRFRWt0b1JBQzJEYlcxM25SREU4elBGd09acnpuQkdianhnQVQtQVpMM0lOT3NuWnY2WFB2VS1reVRPMkJPMkxSMXZ0bHloMU1ydHJEdDJ1TDNzd3JEUzRxNUlCWnNKWm4tZ1YtdXBmdw?oc=5","date":"2025-10-23","type":"regulatory","source":"prnewswire.com","summary":"Apotex Receives Health Canada Approval for LOQTORZI® -- The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer - prnewswire.com","headline":"Apotex Receives Health Canada Approval for LOQTORZI® -- The First and Only Immuno-Therapy for Recurrent Unresectable or ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPM0JRNGN2NVhQUnBOdkFaMU55cjhSM2JCRWVnSlFUcEFWSlpQZHdPN1pSanI1eU80Tmd4OEFidFZyZVNXSWdYY3dkZVd1MjZ4QmEtaGI2RXFRcWlPSy02N091enh0U3FTdzRuZlpKYVRnMHRYWkM4WUdlY2ZGZ0tRM0pHQXBGQ0dVeVplTktzdnoxazdQY09YX2tLZDFmSHZ4LWNvZ0RUbjZ5bVlOcl90U3EybDd2emcyM1E5ajRsbmp4SzYtb3ZZSzhyaExWUFJ0cWx3cHJ6RVlNbWE3NmE3VklEVEFNazRPcWhvUXp5OG1QN2gxUEw1di1Pbm1mbmZXRFlINTdzQTQ?oc=5","date":"2025-10-07","type":"pipeline","source":"prnewswire.com","summary":"Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to \"Linzagolix\" for Uterine Fibroid Treatment - prnewswire.com","headline":"Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to \"Linzagolix\" for Uterine Fibroid Treat","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-12","type":"deal","source":"Medical Dialogues","summary":"Panacea Biotec, Apotex resolve dispute over breach of collaboration agreement - Medical Dialogues","headline":"Panacea Biotec, Apotex resolve dispute over breach of collaboration agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNdlJ5Tm5ReG8wcm10eHZsQ3p0VVNPdmtxU1RydG1Odndpa0gtT2pfOFNISnJMWE9MT0ZRRVJJVjc2TVUzTHdRMnB4RXlJNWtfQVNpM2pWdE1DLXplZ3UtU0kzNjc4bVRlME1BV2NPVVFTclU2RFVPOUx6LWVjbnpQUFV1Z0FCNU9QSHg0Unl1TVF1TXUwUGJiZHpiZ21adWJIcFZ1MkRYNVZCcFZCemhwXzAtbjZMRkh3akctYXZuaG02cEVDOEFONm4xa2RiMy1mZGJVdmhJellqZ2t0dWpmY1hsb0HSAeoBQVVfeXFMTTBqOGFSamhiSUtUZ2NBeVo2c0dYdGVXZDB6Q0UySURNQ0pJZ0ZxNnVDaWdwOF9SY1Z3cDhmbHAtTkhheFZpQlVpRHFoV3psTWlKUXV2a21QU1VwbVcwZWRCOVFvUm5rQV9Ia2pnb1EzNjNOcmNteElUYXh2TDVHM1VIVF9MWWY0U092MldUdllYM3FaRkcyYS02QmQzeW9EZVhnQkFMamx6elJuS0luRlNQTlpKQ29MU3V0dXg0YmQxcVQ4QXA3aFZtVWFsWXV1TWtsZUtpYkNlc1pjLW1iZmE0dmNWTkUwSVln?oc=5","date":"2025-07-10","type":"deal","source":"ET Pharma","summary":"Panacea Biotec, Apotex settle dispute over breach of collaboration agreement - ET Pharma","headline":"Panacea Biotec, Apotex settle dispute over breach of collaboration agreement","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-06","type":"pipeline","source":"prnewswire.com","summary":"Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico - ","headline":"Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate O","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNYlZ3QUV1V0F6d243Y2h5N2N5N19kOTZQdzZrZGhrRUxIX1dldHMxVzBIOEpvWVRJSDRnNnYwNXo4QTNqUkFHTXA2cGJfQ0RkNVNEcGk5WnUxSDhIcmthVkh3QTlvX2I1Y0ZibjNpOFRuRDMyUHFjUm1lQzVnSlREekJIRno1WHBtWW1EdURFTWZ6NFlyTGR4VGkyV2V1ZTdiYzNVWnNOVVB6and1VnNQM3lOclNLU19GeHN1cWp6a2dGTzhpSnZUaw?oc=5","date":"2024-08-07","type":"pipeline","source":"Ophthalmology Times","summary":"Formosa Pharmaceuticals and Apotex Inc. announce licensing agreement of APP13007 in Canada - Ophthalmology Times","headline":"Formosa Pharmaceuticals and Apotex Inc. announce licensing agreement of APP13007 in Canada","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":1,"phase_3":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}